SCHEDULE 13G: Askeladden Capital Management Discloses 5.0% Stake in INTEST CORP
Beneficial Ownership Report (Schedule 13G)
Askeladden Capital Management LLC and Samir Patel have jointly disclosed a 5.0% beneficial ownership stake in INTEST CORP, holding 624,397 shares of common stock.
Summary
- Askeladden Capital Management LLC, a Texas limited liability company, and Samir Patel have jointly filed a Schedule 13G.
- The filing indicates beneficial ownership of 624,397 shares of Common Stock in INTEST CORP.
- This ownership represents 5.0% of INTEST CORP's outstanding Common Stock.
- The percentage is calculated based on 12,373,276 shares outstanding as of March 1, 2025, as reported in INTEST CORP's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
- The shares are held by separately managed accounts on behalf of investment advisory clients of Askeladden Capital Management LLC.
- Askeladden Capital Management LLC is classified as an Investment Adviser (IA), and Samir Patel is classified as an Individual (IN) and Holding Company (HC).
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, carrying a neutral sentiment. It indicates a significant investment but provides no performance or strategic updates to infer positive or negative sentiment.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive investment by an institutional investor, indicating a belief in the long-term value of INTEST CORP without an intent to influence management or control. Such filings are common across various industries when an investment firm crosses the 5% ownership threshold.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional investor holding 5.0% of the common stock may be viewed positively, indicating confidence in the company's value. However, as a passive investment, it does not suggest immediate strategic changes or activist involvement.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Fiscal year end for INTEST CORP's Annual Report on Form 10-K. |
| 2025-03-01 | Date as of which 12,373,276 shares of Common Stock were outstanding, as reported in the Issuer's 10-K. |
| 2025-03-13 | Date INTEST CORP's Annual Report on Form 10-K was filed with the SEC. |
| 2025-04-11 | Date of event which requires filing of this statement (beneficial ownership crossing 5% threshold). |
| 2025-04-14 | Date the Schedule 13G was signed by Askeladden Capital Management LLC and Samir Patel. |
Keywords
INTEST CORP, Askeladden Capital Management, Samir Patel, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, SEC Filing, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.